Carcinoma of bladder
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
To test the hypothesis that common sequence variants in the cell cycle control pathway may affect bladder cancer susceptibility, the effects of a panel of 10 potential functional single nucleotide polymorphisms (SNPs) from 7 cell cycle control genes, P53, P21, P27, CDK4, CDK6, CCND1, and STK15, were evaluated on bladder cancer risk in a case-control study of 696 bladder cancer cases and 629 healthy controls.
|
18361427 |
2008 |
Carcinoma of bladder
|
0.090 |
Biomarker
|
disease |
BEFREE |
Downregulated GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6, and thus may be helpful in the development of effective treatment strategies against bladder cancer.
|
24069260 |
2013 |
Carcinoma of bladder
|
0.090 |
Biomarker
|
disease |
BEFREE |
Moreover, we demonstrated miR-320c could induce bladder cancer cell cycle arrest and mobility via regulating CDK6.
|
25178497 |
2014 |
Carcinoma of bladder
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Flow cytometric analysis of the cell cycle showed that miR-892b-transfected bladder cancer cells were subject to arrest in the G1 phase, which was due to the downregulation of cyclin D1 and CDK6 followed by upregulation of p19ARF.
|
27573859 |
2016 |
Carcinoma of bladder
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Further research suggested that METTL13 negatively regulates cell proliferation in bladder cancer and reinstates G1/S checkpoint via the coordinated downregulation of CDK6, CDK4 and CCND1, decreased phosphorylation of Rb and subsequent delayed cell cycle progression.
|
26763933 |
2016 |
Carcinoma of bladder
|
0.090 |
Biomarker
|
disease |
BEFREE |
Screening differential circular RNA expression profiles reveals the regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 pathway in bladder carcinoma.
|
27484176 |
2016 |
Carcinoma of bladder
|
0.090 |
Biomarker
|
disease |
BEFREE |
To conclude, we propose 2 novel regulatory circuits mediated by miR-381-3p in BCa, which may assist in the development of more effective therapies against BCa in the future.-Li, J., Ying, Y., Xie, H., Jin, K., Yan, H., Wang, S., Xu, M., Xu, X., Wang, X., Yang, K., Zheng, X., Xie, L. Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression is blocked by miR-381-3p in bladder cancer.
|
30138038 |
2019 |
Carcinoma of bladder
|
0.090 |
Biomarker
|
disease |
BEFREE |
Collectively, this study not only establishes a novel regulatory axis of miR-934/UBE2N of CDK6 but also provides data suggesting that miR-934 and UBE2N may be potentially promising targets for therapeutic strategies against BC.-Yan, H., Ren, S., Lin, Q., Yu, Y., Chen, C., Hua, X., Jin, H., Lu, Y., Zhang, H., Xie, Q., Huang, C., Huang, H. Inhibition of UBE2N-dependent CDK6 protein degradation by miR-934 promotes human bladder cancer cell growth.
|
31373842 |
2019 |
Carcinoma of bladder
|
0.090 |
Biomarker
|
disease |
BEFREE |
MiR-145-5p suppressed cell growth and migration ability in BC, whereas CDK6 exerted the opposite influence on these cellular events.
|
30362519 |
2019 |